cp wire

CP Wire Articles

Johnson & Johnson announced on 6/13/2018 that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive guidance for Tremfya® (guselkumab), following... read more

Wed, 06/13/18 - 10:25 am

This article is part of a series on right-to-try and the FDA. Please click here to read the first article in the series.

Unfortunately we haven'... read more

Tue, 06/12/18 - 11:38 am
CP Staff

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) announced on 6/12/2018 positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of... read more

Tue, 06/12/18 - 10:04 am

Sage Therapeutics (NASDAQ: SAGE) announced on 6/12/2018 its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA).... read more

Tue, 06/12/18 - 09:42 am

Hu-manity.co, a company designed to create decentralized human rights using proprietary technology and legal innovations on blockchains, has partnered with Orb Health, a leading provider of cloud-... read more

Tue, 06/12/18 - 09:29 am

Eli Lilly (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer'... read more

Tue, 06/12/18 - 09:02 am
Key points of the Biopred panel: 
  • Without extraction - no biases associated to extractions steps
  • More than 2100 mRNA target... read more
Mon, 06/11/18 - 10:12 am
CP Staff

Results from a new clinical study have confirmed the safety and tolerability of using bacteria-specific viruses known as bacteriophages to eliminate disease-causing bacteria in the gut. The new... read more

Mon, 06/11/18 - 10:02 am
  •  Company just announced 24% cut in workforce
  • First patient is being treated for non-small cell lung cancer
  • ADXS-NEO generates T cell responses against neoantigen peptides... read more
Mon, 06/11/18 - 09:33 am

  • Atogepant met primary endpoint for all doses and dose regimens
  • Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over... read more
Mon, 06/11/18 - 09:07 am

Genentech, announced on 6/8/2018 that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a... read more

Fri, 06/8/18 - 09:53 am

Magenta Therapeutics  announced on 6/8/2018 that it has launched an initial public offering of its common stock. Magenta is offering 6,666,667 shares of its common stock, subject to market and... read more

Fri, 06/8/18 - 09:43 am

Lundbeck A/S (Lundbeck) announced on 6/6/2018 that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ) investigation related to... read more

Thu, 06/7/18 - 09:56 am

Pfizer Inc. (NYSE:PFE) announced on 6/7/2018 that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for... read more

Thu, 06/7/18 - 09:34 am

AmpliPhi Biosciences Corporation (NYSE American: APHB) announced on 5/7/2018 a poster presentation of a successful case study of a patient with cystic fibrosis, suffering from recurrent multi-drug... read more

Thu, 06/7/18 - 09:20 am

The right-to-try legislation guaranteeing that the FDA cannot deny patients the right to try experimental drugs was both championed and criticized by many groups. The conservative/... read more

Wed, 06/6/18 - 01:29 pm
CP Staff

Peloton Therapeutics, Inc., announced on 6/6/2018 the dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent, PT2977, to treat von... read more

Wed, 06/6/18 - 09:33 am
  • Axovant will license two products from Oxford BioMedica
  • The gene therapy based products have demonstrated long term improvement in motor function
  • Axovant shares are up 102%... read more
Wed, 06/6/18 - 09:17 am

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued... read more

Tue, 06/5/18 - 09:51 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.